Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Receivables: 2009-2024

Historic Receivables for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Dec 2024 value amounting to $81.9 million.

  • Ironwood Pharmaceuticals' Receivables rose 58.00% to $120.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $328.3 million, marking a year-over-year decrease of 2.13%. This contributed to the annual value of $81.9 million for FY2024, which is 36.57% down from last year.
  • Per Ironwood Pharmaceuticals' latest filing, its Receivables stood at $81.9 million for FY2024, which was down 36.57% from $129.1 million recorded in FY2023.
  • Ironwood Pharmaceuticals' 5-year Receivables high stood at $145.8 million for FY2020, and its period low was $81.9 million during FY2024.
  • Over the past 3 years, Ironwood Pharmaceuticals' median Receivables value was $129.1 million (recorded in 2023), while the average stood at $113.7 million.
  • Data for Ironwood Pharmaceuticals' Receivables shows a maximum YoY plummeted of 36.57% (in 2024) over the last 5 years.
  • Ironwood Pharmaceuticals' Receivables (Yearly) stood at $145.8 million in 2020, then decreased by 5.35% to $138.0 million in 2021, then dropped by 5.80% to $130.0 million in 2022, then dropped by 0.68% to $129.1 million in 2023, then plummeted by 36.57% to $81.9 million in 2024.